A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Public ClinicalTrials.gov record NCT05243550. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-102 as Primary Chemoablative Therapy in Patients With Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC) at Intermediate Risk (IR) of Recurrence
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This Phase 3, multinational, single-arm study was designed to evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
Study identification
- NCT ID
- NCT05243550
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 240 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 1, 2022 (Actual)
- Primary completion
- Apr 26, 2023 (Actual)
- Completion
- Mar 2028 (Estimated)
- Last update posted
- May 11, 2026
2022 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Arizona Urology Specialists | Tucson | Arizona | 85704 | — |
| Loma Linda University Medical Center | Loma Linda | California | 92350 | — |
| Genesis Research | San Diego | California | 92123 | — |
| Wichita Urology Group | Wichita | Kansas | 67226 | — |
| John Hopkins University | Baltimore | Maryland | 21218 | — |
| Chesapeake Urology Research Associates | Hanover | Maryland | 21076 | — |
| University of Missouri | Columbia | Missouri | 65212 | — |
| Atlantic Health System | Morristown | New Jersey | 07960 | — |
| Great Lakes Physician dba WNY Urology Associates | Cheektowaga | New York | 14225 | — |
| AccuMed Research Associates | Garden City | New York | 11530 | — |
| Manhattan Medical Research | New York | New York | 10016 | — |
| NYU Langone Health | New York | New York | 10016 | — |
| Mount Sinai | New York | New York | 10029 | — |
| Urology Associates, P.C. | Nashville | Tennessee | 37209 | — |
| Houston Methodist Research Institute | Houston | Texas | 77030 | — |
| Spokane Urology, P.S. | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 49 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05243550, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05243550 live on ClinicalTrials.gov.